O-methyl (S)-N-[3-[4-(4-tert-butoxycarbonylpiperazin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methylthiocarbamate | 268208-30-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: O-methyl (S)-N-[3-[4-(4-tert-butoxycarbonylpiperazin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methylthiocarbamate
• 英文别名: (S)-t-butyl 4-(2-fluoro-4-(5-((methoxycarbonothioylamino)methyl)-2-oxo-oxazolidin-3-yl)phenyl)piperazine-1-carboxylate；(S)-t-butyl 4-(2-fluoro-4-(5-((methoxycarbonothioylamino) methyl)-2-oxooxazolidin-3-yl)phenyl)piperazine-1-carboxylate；tert-butyl 4-[2-fluoro-4-[(5S)-5-[(methoxycarbothioylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl]phenyl]piperazine-1-carboxylate
• CAS: 268208-30-6
• 化学式: C₂₁H₂₉FN₄O₅S
• 分子量: 468.549
• InChiKey: KXUVXOBRNIBPOD-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  O-methyl (S)-N-[3-[4-(4-tert-butoxycarbonylpiperazin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methylthiocarbamate 在 三氟乙酸 、 碳酸氢钠 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 3.25h， 以99%的产率得到{[(5S)-3-[3-fluoro-(1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl]methyl}-carbamothioic acid methyl ester
  参考文献：
  名称：

  WO2009/1192

  摘要：

  公开号：
• 作为产物：
  描述：

  甲醇 、 (R)-t-butyl 4-(2-fluoro-4-(5-(isothiocyanatomethyl)-2-oxo-oxazolidin-3-yl)phenyl)piperazine-1-carboxylate 反应 6.0h， 以60%的产率得到O-methyl (S)-N-[3-[4-(4-tert-butoxycarbonylpiperazin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methylthiocarbamate
  参考文献：
  名称：

  WO2009/1192

  摘要：

  公开号：

文献信息

• NOVEL COMPOUND AND THEIR USE
  申请人：Pushpan Simi

  公开号：US20100234390A1

  公开（公告）日：2010-09-16

  The present invention provides novel compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The novel compounds are useful as antibacterial agents in the treatment of conditions such as nosocomial pneumonia, community acquired pneumonia, infections caused by vancomycin resistant enterococci (VRE), methicillin resistant Staphylococcus aureus (MRSA), Heamophilus influenzae (HI) and penicillin resistant Streptococcus pneumoniae (PRSP). The compounds of the present invention are effective against a number of human or animal pathogens including VRE, PRSP, HI and MRSA.

  本发明提供了一般式（I）的新化合物，它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、水合物、溶剂化物、药学上可接受的盐和组合物、代谢物和前药。这些新化合物可用作抗菌剂，用于治疗诸如医院获得性肺炎、社区获得性肺炎、由耐万古霉素肠球菌（VRE）、耐甲氧西林金黄色葡萄球菌（MRSA）、流感嗜血杆菌（HI）和耐青霉素的肺炎链球菌（PRSP）引起的感染等疾病。本发明的化合物对包括VRE、PRSP、HI和MRSA在内的许多人类或动物病原体都有效。
• Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents
  作者：Mohamed Takhi、Gurpreet Singh、C. Murugan、Nirvesh Thaplyyal、Soma Maitra、K.M. Bhaskarreddy、P.V.S. Amarnath、Arundhuti Mallik、T. Harisudan、Ravi Kumar Trivedi、K. Sreenivas、N. Selvakumar、Javed Iqbal

  DOI：10.1016/j.bmcl.2008.03.043

  日期：2008.9

  Novel oxazolidinone antibacterials bearing a variety of 3-indolylglyoxamide substituents have been explored in an effort to improve the spectrum and potency of this class of agents. A subclass of this series was also made with the diversity at C-5 terminus. These derivatives have been screened against a panel of clinically relevant Gram-positive pathogens and fastidious Gram-negative organisms. Several analogs in this series were identified with in vitro activity superior to linezolid ( MIC = 0.25-2 mu g/ mL). Compounds 10a, 10c, 10e and 10f displayed activity against linezolid resistant Gram-positive organisms (MIC = 2-4 mu g/ mL). Selected oxazolidinones were evaluated for in vivo efficacy against a mouse systemic infection model. (C) 2008 Elsevier Ltd. All rights reserved.
• NOVEL COMPOUNDS AND THEIR USE
  申请人：Orchid Research Laboratories Limited

  公开号：EP2170874A2

  公开（公告）日：2010-04-07
• [EN] NOVEL COMPOUNDS AND THEIR USE<br/>[FR] NOUVEAUX COMPOSÉS ET LEUR UTILISATION
  申请人：ORCHID RES LAB LTD

  公开号：WO2009001192A2

  公开（公告）日：2008-12-31

  [EN] The present invention provides novel compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The novel compounds are useful as antibacterial agents in the treatment of conditions such as nosocomial pneumonia, community acquired pneumonia, infections caused by vancomycin resistant enterococci (VRE), methicillin resistant Staphylococcus aureus (MRSA), Heamophilus influenzae (HI) and penicillin resistant Streptococcus pneumoniae (PRSP). The compounds of the present invention are effective against a number of human or animal pathogens including VRE, PRSP, HI and MRSA.
  [FR] La présente invention concerne de nouveaux composés représentés par la formule générale (i), leurs dérivés, analogues, formes tautomères, stéréoisomères, polymorphes, hydrates, solvates, sels pharmaceutiquement acceptables ainsi que leurs compositions, métabolites et promédicaments. Les nouveaux composés se révèlent utiles en tant qu'agents antibactériens pour le traitement de pathologies telles qu'une pneumonie nosocomiale, une pneumonie acquise dans la collectivité, des infections causées par des entérocoques résistants à la vancomycine (ERV) et des bactéries telles que Staphylococcus aureus résistant à la méthicilline (SARM), Heamophilus influenzae (HI) et Streptococcus pneumoniae résistant à la pénicilline (SPRP). Les composés de la présente invention se révèlent efficaces contre un certain nombre de pathogènes humains ou animaux, notamment ERV, SPRP, HI et SARM.
• WO2009/1192
  申请人：——

  公开号：——

  公开（公告）日：——